Stay updated with breaking news from Katherine trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more. ....